Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.50 USD
-0.02 (-0.57%)
Updated May 6, 2024 04:00 PM ET
After-Market: $3.50 0.00 (0.00%) 5:38 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 21 - 40 ( 398 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Additional Anaphylm Pharmacokinetic Data Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Crossover Study Validates Dosing Instructions; Pivotal PK Study in Q4:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
NDA Submitted for Libervant in 2-5yo; FDA Acceptance of NDA Likely in Q3:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Neffy Developments May Bode Well for Anaphylm, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive Anaphylm- Clinical Data; Pivotal Trial Starting Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Additional Studies Support Anaphylm''s Fast Time to Rescue; Pivotal Study in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Upcoming Epi Alternative AdCom & Read Through to AQST-109; Q1:23 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Eyes Remain on AQST-109; Libervant License Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
U/g to OP Due to Extended Cash Runway; AQST-109/Anaphylaxis Updates; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
KOL Call Invite: Shaking up the Epi Market with No-Needle Alternatives
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Assuming at Neutral & $3 PT; On A QUEST to Disrupt the Anaphylaxis Market;
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-109 End-of-Phase 2 Meeting Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EOP2 Minutes Sets the Stage for Pivotal PK Study for AQST-109 in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EoP2 Meeting For AQST-109 in Q4; Libervant Updates; Q3 Financials
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L